
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
Short Title: A032102
Enrollment Status: Recruiting
NCT #: A032102
Specialty Area: Oncology
Condition Studied: Prostate Cancer
Age Groups: Adult; Older Adult
Phase: II
Study Information
Summary / Purpose
The purpose of this study is to test whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing.
Who Can Participate
- Adult males 18+ years of age
- Confirmed progressive castration resistant prostate cancer
- Must have measurable disease
- No prior treatment with cabazitaxel plus carboplatin
What's Involved
- Submitting tumor tissue from a previous surgery or biopsy for genetic testing to look for changes in the DNA and RNA of your cancer
- Assignment to a treatment group based on the results of that genetic testing
- Study treatment based on your assigned group, which may include chemotherapy given through a vein (IV), hormone therapy taken by mouth, a targeted therapy called valemetostat tosylate, or a radioligand therapy given through a vein that delivers radiation directly to tumor cells
- Imaging with computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, bone scans, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans, and fludeoxyglucose (FDG) positron emission tomography (PET) scans
- Sample collection for research, including blood samples during treatment
- Completing questionnaires about your symptoms and side effects
Principal Investigator

Additional Information
Address: 1500 E 2nd St. Reno, NV 89502
General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org
Complete Study Details: https://clinicaltrials.gov/study/NCT06632977
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.